Zhang L, Wu ZY, Li J, Lin Y, et al. Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide
Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART):
Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial. Int J Cancer 2021 Sep 30. doi: 10.1002/ijc.33830.
PMID: 34591977